heXem bio is developing therapies designed to restore the function of aging blood-forming stem cells. Its approach recreates a supportive early-development environment outside the body, aiming to rejuvenate the cells that replenish blood and immune systems. The initial program targets better bone marrow transplant outcomes for patients with blood cancer. [1]
The company's scientific foundation includes technology licensed from the University of Pittsburgh, connecting developmental biology with the pursuit of healthier aging. In 2026, heXem bio announced a $10.4 million seed round led by Draper Associates to advance its blood stem cell rejuvenation platform. [2] [3]